Lowest-Rated StocksLowest-RatedNASDAQ:DOCS Doximity (DOCS) Stock Price, News & Analysis → New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad) Free DOCS Stock Alerts $24.93 +0.11 (+0.44%) (As of 10:16 AM ET) Add Compare Share Share Today's Range$24.74▼$25.1550-Day Range$24.82▼$30.4652-Week Range$19.71▼$37.06Volume140,195 shsAverage Volume1.74 million shsMarket Capitalization$4.65 billionP/E Ratio37.77Dividend YieldN/APrice Target$28.82 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Doximity alerts: Email Address Doximity MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside16.1% Upside$28.82 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.21Based on 5 Articles This WeekInsider TradingSelling Shares$67,425 Sold Last QuarterProj. Earnings Growth6.94%From $0.72 to $0.77 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.08 out of 5 starsMedical Sector405th out of 918 stocksCustom Computer Programming Services Industry12th out of 23 stocks 3.0 Analyst's Opinion Consensus RatingDoximity has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 10 hold ratings, and 2 sell ratings.Amount of Analyst CoverageDoximity has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for DOCS. Previous Next 0.0 Dividend Strength Dividend YieldDoximity does not currently pay a dividend.Dividend GrowthDoximity does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DOCS. Previous Next 2.3 News and Social Media Coverage News SentimentDoximity has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Doximity this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for DOCS on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows10 people have added Doximity to their MarketBeat watchlist in the last 30 days. This is an increase of 11% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Doximity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $67,425.00 in company stock.Percentage Held by Insiders39.40% of the stock of Doximity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.19% of the stock of Doximity is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Doximity are expected to grow by 6.94% in the coming year, from $0.72 to $0.77 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Doximity is 37.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.92.Price to Earnings Ratio vs. SectorThe P/E ratio of Doximity is 37.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 191.64.Price to Earnings Growth RatioDoximity has a PEG Ratio of 3.15. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDoximity has a P/B Ratio of 4.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe only accurate crypto trading system I know …Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.Here's what our expert says you should buy before April 14. About Doximity Stock (NASDAQ:DOCS)Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.Read More DOCS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DOCS Stock News HeadlinesApril 3, 2024 | insidertrades.comKira Scherer Wampler Sells 2,500 Shares of Doximity, Inc. (NASDAQ:DOCS) StockApril 18, 2024 | markets.businessinsider.comGrabar Law Office Investigates Claims on Behalf of Shareholders of Doximity, Inc. (DOCS)April 19, 2024 | Weiss Ratings (Ad)The only accurate crypto trading system I know …Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.April 17, 2024 | businesswire.comInvestor Alert: Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against Doximity, Inc. and Encourages Investors With Losses to Contact the Firm (NYSE: DOCS)April 16, 2024 | americanbankingnews.comAnalyzing TruBridge (NASDAQ:TBRG) and Doximity (NASDAQ:DOCS)April 12, 2024 | money.usnews.comDoximity Inc - Ordinary Shares - Class AApril 12, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCSApril 6, 2024 | stockhouse.comDoximity, Inc. (DOCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsApril 19, 2024 | Weiss Ratings (Ad)The only accurate crypto trading system I know …Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.April 5, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Doximity, Inc. (DOCS) on Behalf of InvestorsApril 5, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Doximity, Inc. (DOCS) on Behalf of InvestorsApril 5, 2024 | nasdaq.comInteresting DOCS Put And Call Options For March 2025April 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCSApril 3, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces Investigation of Doximity, Inc. (DOCS) on Behalf of InvestorsApril 2, 2024 | markets.businessinsider.com6 Analysts Assess Doximity: What You Need To KnowApril 1, 2024 | stockhouse.comROSEN, LEADING INVESTOR COUNSEL, Encourages Doximity, Inc. Investors to Inquire About Securities Class Action Investigation - DOCSMarch 26, 2024 | msn.comAnalyst issues a warning as Reddit stock 'goes to the moon'March 18, 2024 | finance.yahoo.comDOCS Apr 2024 37.500 callMarch 15, 2024 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About DoximityMarch 13, 2024 | wsj.comDoximity Inc.February 27, 2024 | msn.comLeerink Partners Initiates Coverage of Doximity (DOCS) with Market Perform RecommendationFebruary 26, 2024 | markets.businessinsider.comForecasting The Future: 5 Analyst Projections For DoximityFebruary 25, 2024 | ca.finance.yahoo.comDOCS Apr 2024 40.000 callFebruary 25, 2024 | msn.comDoximity (DOCS) Price Target Increased by 5.88% to 29.66February 24, 2024 | msn.comAnalysts Predict 2024 Will Be a ‘Stock Picker’s Paradise’: 4 Stocks To Buy Now To Ride Next Year’s Market UpswingFebruary 22, 2024 | businesswire.comDoximity to Participate in Upcoming Investor EventsFebruary 21, 2024 | fool.com2 Beaten-Down Stocks to Buy and Hold for 10 YearsSee More Headlines Receive DOCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Doximity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/08/2024Today4/19/2024Next Earnings (Estimated)5/21/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Custom computer programming services Sub-IndustryN/A Current SymbolNASDAQ:DOCS CUSIPN/A CIK1516513 Webwww.doximity.com Phone650-549-4330FaxN/AEmployees977Year FoundedN/APrice Target and Rating Average Stock Price Target$28.82 High Stock Price Target$33.00 Low Stock Price Target$23.00 Potential Upside/Downside+16.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)$0.66 Trailing P/E Ratio37.61 Forward P/E Ratio34.47 P/E Growth3.15Net Income$112.82 million Net Margins29.39% Pretax Margin37.15% Return on Equity16.08% Return on Assets13.76% Debt Debt-to-Equity RatioN/A Current Ratio8.03 Quick Ratio8.03 Sales & Book Value Annual Sales$419.05 million Price / Sales11.05 Cash Flow$0.71 per share Price / Cash Flow34.88 Book Value$4.98 per share Price / Book4.98Miscellaneous Outstanding Shares186,550,000Free Float113,052,000Market Cap$4.63 billion OptionableNot Optionable Beta1.17 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Jeffrey A. Tangney (Age 51)Co-Founder, CEO & Chairperson Comp: $243.73kDr. Nate Gross M.D. (Age 40)Co-Founder & Chief Strategy Officer Comp: $455.54kMs. Anna Bryson (Age 34)Chief Financial Officer Comp: $453.71kMs. Jennifer W. Chaloemtiarana (Age 56)General Counsel & Corporate Secretary Comp: $504.04kMr. Paul Jorgensen (Age 53)Chief Revenue Officer Comp: $455.13kMs. Shari BuckCo-founder and SVP People & OpsMr. Jey BalachandranChief Technology OfficerMr. Perry Scott GoldHead of Investor RelationsJim RivasHead of Corporate CommunicationsMr. Bruno MirandaSenior VP of EngineeringMore ExecutivesKey CompetitorsMadrigal PharmaceuticalsNASDAQ:MDGLGlaukosNYSE:GKOSOrganon & Co.NYSE:OGNKrystal BiotechNASDAQ:KRYSHalozyme TherapeuticsNASDAQ:HALOView All CompetitorsInsiders & InstitutionsState of Michigan Retirement SystemBought 1,700 shares on 4/18/2024Ownership: 0.016%Allspring Global Investments Holdings LLCBought 21,653 shares on 4/18/2024Ownership: 0.012%Oak Thistle LLCBought 12,004 shares on 4/18/2024Ownership: 0.006%PFS Partners LLCSold 1,000 shares on 4/16/2024Ownership: 0.001%RFG Advisory LLCBought 1,401 shares on 4/11/2024Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions DOCS Stock Analysis - Frequently Asked Questions Should I buy or sell Doximity stock right now? 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Doximity in the last twelve months. There are currently 2 sell ratings, 10 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" DOCS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DOCS, but not buy additional shares or sell existing shares. View DOCS analyst ratings or view top-rated stocks. What is Doximity's stock price target for 2024? 14 brokers have issued 1-year price targets for Doximity's shares. Their DOCS share price targets range from $23.00 to $33.00. On average, they predict the company's stock price to reach $28.82 in the next year. This suggests a possible upside of 16.1% from the stock's current price. View analysts price targets for DOCS or view top-rated stocks among Wall Street analysts. How have DOCS shares performed in 2024? Doximity's stock was trading at $28.04 at the beginning of the year. Since then, DOCS stock has decreased by 11.5% and is now trading at $24.82. View the best growth stocks for 2024 here. When is Doximity's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our DOCS earnings forecast. How were Doximity's earnings last quarter? Doximity, Inc. (NASDAQ:DOCS) announced its earnings results on Thursday, February, 8th. The company reported $0.25 EPS for the quarter, beating analysts' consensus estimates of $0.19 by $0.06. The business earned $135.28 million during the quarter, compared to the consensus estimate of $127.46 million. Doximity had a trailing twelve-month return on equity of 16.08% and a net margin of 29.39%. What ETFs hold Doximity's stock? ETFs with the largest weight of Doximity (NASDAQ:DOCS) stock in their portfolio include Jacob Forward ETF (JFWD), Global X Telemedicine & Digital Health ETF (EDOC), Janus Henderson Small Cap Growth Alpha ETF (JSML), Fidelity Digital Health ETF (FDHT), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Renaissance IPO ETF (IPO) and Pacer US Large Cap Cash Cows Growth Leaders ETF (COWG). What guidance has Doximity issued on next quarter's earnings? Doximity updated its FY 2024 earnings guidance on Thursday, February, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $473.3 million-$474.3 million, compared to the consensus revenue estimate of $467.3 million. When did Doximity IPO? Doximity (DOCS) raised $501 million in an IPO on Thursday, June 24th 2021. The company issued 23,300,000 shares at $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan Securities served as the underwriters for the IPO and Piper Sandler, William Blair, Canaccord and Raymond James were co-managers. Who are Doximity's major shareholders? Doximity's stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Capital LLC (0.04%), Apella Capital LLC (0.03%), State of Michigan Retirement System (0.02%), RFG Advisory LLC (0.01%), Allspring Global Investments Holdings LLC (0.01%) and NBC Securities Inc. (0.01%). Insiders that own company stock include Anna Bryson, Craig Overpeck, Gilbert H Kliman, Interwest Partners X Lp, Joseph B Kleine, Kevin Spain, Kira Scherer Wampler, Paul W Jorgensen and Timothy S Cabral. View institutional ownership trends. How do I buy shares of Doximity? Shares of DOCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DOCS) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIThe #1 Crypto for 2024InvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsHow Biden has already won 2024Porter & CompanyUrgent alert: open this for a huge profit potentialTimothy SykesMy biggest AI fearParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Doximity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.